GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (BUE:AZN) » Definitions » E10

AstraZeneca (BUE:AZN) E10 : ARS3.76 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is AstraZeneca E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

AstraZeneca's adjusted earnings per share data for the three months ended in Mar. 2024 was ARS1,179.500. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ARS3.76 for the trailing ten years ended in Mar. 2024.

During the past 12 months, AstraZeneca's average E10 Growth Rate was 15.40% per year. During the past 3 years, the average E10 Growth Rate was -5.10% per year. During the past 5 years, the average E10 Growth Rate was -9.00% per year. During the past 10 years, the average E10 Growth Rate was -8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of AstraZeneca was 77.50% per year. The lowest was -26.20% per year. And the median was 0.50% per year.

As of today (2024-05-23), AstraZeneca's current stock price is ARS214.50. AstraZeneca's E10 for the quarter that ended in Mar. 2024 was ARS3.76. AstraZeneca's Shiller PE Ratio of today is 57.05.

During the past 13 years, the highest Shiller PE Ratio of AstraZeneca was 75.22. The lowest was 4.62. And the median was 23.76.


AstraZeneca E10 Historical Data

The historical data trend for AstraZeneca's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca E10 Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.54 6.09 4.08 3.02 3.60

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.09 3.21 3.27 3.60 3.76

Competitive Comparison of AstraZeneca's E10

For the Drug Manufacturers - General subindustry, AstraZeneca's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Shiller PE Ratio falls into.



AstraZeneca E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1179.5/131.6000*131.6000
=1,179.500

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

per share eps CPI Adj_EPS
201406 5.119 99.800 6.750
201409 1.684 100.000 2.216
201412 -2.138 99.900 -2.816
201503 3.881 99.600 5.128
201506 4.998 100.100 6.571
201509 5.641 100.200 7.409
201512 8.154 100.400 10.688
201603 7.448 100.400 9.763
201606 -0.033 101.000 -0.043
201609 11.933 101.500 15.472
201612 22.986 102.200 29.598
201703 6.475 102.700 8.297
201706 6.265 103.500 7.966
201709 9.463 104.300 11.940
201712 19.668 105.000 24.651
201803 5.440 105.100 6.812
201806 6.734 105.900 8.368
201809 12.512 106.600 15.446
201812 30.918 107.100 37.991
201903 18.372 107.000 22.596
201906 4.021 107.900 4.904
201909 12.863 108.400 15.616
201912 14.346 108.500 17.400
202003 36.621 108.600 44.377
202006 39.707 108.800 48.028
202009 36.378 109.200 43.840
202012 63.476 109.400 76.357
202103 106.294 109.700 127.514
202106 39.787 111.400 47.002
202109 -107.558 112.400 -125.931
202112 -22.218 114.700 -25.492
202203 26.843 116.500 30.322
202206 27.676 120.500 30.225
202209 145.897 122.300 156.991
202212 97.237 125.300 102.126
202303 229.158 126.800 237.833
202306 280.800 129.400 285.574
202309 307.956 130.100 311.507
202312 223.820 130.500 225.707
202403 1,179.500 131.600 1,179.500

Add all the adjusted EPS together and divide 10 will get our e10.


AstraZeneca  (BUE:AZN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AstraZeneca's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=214.50/3.76
=57.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of AstraZeneca was 75.22. The lowest was 4.62. And the median was 23.76.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


AstraZeneca E10 Related Terms

Thank you for viewing the detailed overview of AstraZeneca's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (BUE:AZN) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (BUE:AZN) Headlines

From GuruFocus

AstraZeneca: Growth Is Still a Better Choice

By Nathan Aisenstadt 11-15-2023